IDH1 and IDH2 mutations in myeloid neoplasms--novel paradigms and clinical implications.
作者信息
Cazzola Mario
出版信息
Haematologica. 2010 Oct;95(10):1623-7. doi: 10.3324/haematol.2010.030015.
Abstract
摘要
相似文献
1
IDH1 and IDH2 mutations in myeloid neoplasms--novel paradigms and clinical implications.
Haematologica. 2010 Oct;95(10):1623-7. doi: 10.3324/haematol.2010.030015.
2
IDH1 and IDH2 mutations are rare in pediatric myeloid malignancies.
Leukemia. 2011 Feb;25(2):382-4. doi: 10.1038/leu.2010.307. Epub 2011 Jan 14.
3
Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms.
N Engl J Med. 2010 Jan 28;362(4):369-70. doi: 10.1056/NEJMc0910063.
4
Acquired somatic mutations of isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) in preleukemic disorders.
Blood Cells Mol Dis. 2015 Mar;54(3):286-91. doi: 10.1016/j.bcmd.2014.11.017. Epub 2014 Nov 26.
5
Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms.
Leukemia. 2010 May;24(5):1094-6. doi: 10.1038/leu.2010.52. Epub 2010 Apr 8.
6
TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms.
Ann Hematol. 2012 Apr;91(4):533-41. doi: 10.1007/s00277-011-1330-0. Epub 2011 Sep 9.
7
IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms.
Leukemia. 2010 Jun;24(6):1146-51. doi: 10.1038/leu.2010.77. Epub 2010 Apr 22.
8
Roles of IDH1/2 and TET2 mutations in myeloid disorders.
Int J Hematol. 2016 Jun;103(6):627-33. doi: 10.1007/s12185-016-1973-7. Epub 2016 Mar 15.
9
IDH1 R132H mutation is a rare event in myeloproliferative neoplasms as determined by a mutation specific antibody.
Haematologica. 2010 Oct;95(10):1797-8. doi: 10.3324/haematol.2010.024430. Epub 2010 Jun 9.
10
Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
J Hematol Oncol. 2012 Mar 7;5:5. doi: 10.1186/1756-8722-5-5.
引用本文的文献
1
Targeting of Mutant Isocitrate Dehydrogenase in Glioma: A Systematic Review.
Cancers (Basel). 2025 Aug 12;17(16):2630. doi: 10.3390/cancers17162630.
2
Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasm.
Br J Haematol. 2025 Apr;206(4):1121-1128. doi: 10.1111/bjh.19944. Epub 2024 Dec 19.
3
Differentiating Inhibition Selectivity and Binding Affinity of Isocitrate Dehydrogenase 1 Variant Inhibitors.
J Med Chem. 2023 Apr 13;66(7):5279-5288. doi: 10.1021/acs.jmedchem.3c00203. Epub 2023 Mar 23.
4
Roles of metal ions in the selective inhibition of oncogenic variants of isocitrate dehydrogenase 1.
Commun Biol. 2021 Nov 1;4(1):1243. doi: 10.1038/s42003-021-02743-5.
5
Bridging Cancer Biology with the Clinic: Comprehending and Exploiting IDH Gene Mutations in Gliomas.
Cancer Genomics Proteomics. 2018 Sep-Oct;15(5):421-436. doi: 10.21873/cgp.20101.
6
Loss of 5-Hydroxymethylcytosine Is an Independent Unfavorable Prognostic Factor for Esophageal Squamous Cell Carcinoma.
PLoS One. 2016 Apr 6;11(4):e0153100. doi: 10.1371/journal.pone.0153100. eCollection 2016.
7
Histiocytoid Sweet's syndrome in a patient with myelodsyplastic syndrome: report and review of the literature.
Dermatol Pract Concept. 2016 Jan 31;6(1):9-13. doi: 10.5826/dpc.0601a04. eCollection 2016 Jan.
8
Detection of mutations in myeloid malignancies through paired-sample analysis of microdroplet-PCR deep sequencing data.
J Mol Diagn. 2014 Sep;16(5):504-518. doi: 10.1016/j.jmoldx.2014.05.006. Epub 2014 Jul 10.
9
Molecular pathogenesis of myelodysplastic syndromes.
Transl Med UniSa. 2014 Feb 4;8:19-30. eCollection 2014 Jan.
10
Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies.
Oncotarget. 2011 Jun;2(6):485-90. doi: 10.18632/oncotarget.281.
本文引用的文献
1
IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status.
Blood. 2010 Dec 16;116(25):5486-96. doi: 10.1182/blood-2010-02-267955. Epub 2010 Aug 30.
2
IDH mutations in glioma and acute myeloid leukemia.
Trends Mol Med. 2010 Sep;16(9):387-97. doi: 10.1016/j.molmed.2010.07.002. Epub 2010 Aug 5.
3
A single-tube, sensitive multiplex method for screening of isocitrate dehydrogenase 1 (IDH1) mutations.
Blood. 2010 Jul 22;116(3):495-6. doi: 10.1182/blood-2010-04-280636.
4
The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status.
Blood. 2010 Oct 14;116(15):2779-82. doi: 10.1182/blood-2010-02-270926. Epub 2010 Jul 22.
5
Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group.
J Clin Oncol. 2010 Aug 10;28(23):3717-23. doi: 10.1200/JCO.2010.28.2285. Epub 2010 Jul 12.
6
Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes.
Nat Genet. 2010 Aug;42(8):665-7. doi: 10.1038/ng.620. Epub 2010 Jul 4.
7
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders.
Nat Genet. 2010 Aug;42(8):722-6. doi: 10.1038/ng.621. Epub 2010 Jul 4.
8
IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
J Clin Oncol. 2010 Aug 1;28(22):3636-43. doi: 10.1200/JCO.2010.28.3762. Epub 2010 Jun 21.
9
Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value.
Blood. 2010 Sep 23;116(12):2122-6. doi: 10.1182/blood-2009-11-250878. Epub 2010 Jun 10.
10
IDH1 R132H mutation is a rare event in myeloproliferative neoplasms as determined by a mutation specific antibody.
Haematologica. 2010 Oct;95(10):1797-8. doi: 10.3324/haematol.2010.024430. Epub 2010 Jun 9.
Zotero 插件